Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengzhou Univ. METTL3 compound 16e: sourced facts only. name: "The representative compound 16e showed an IC50 value of 0.49 ± 0.30 nM against METTL3." [PMID:40939495]; target: "The representative compound 16e showed an IC50 value of 0.49 ± 0.30 nM against METTL3." [PMID:40939495]; developer: "Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, 450052, China; Henan Sino-US International Joint Laboratory of Clinical Pharmacy, Zhengzhou, 450052, China." [PMID:40939495]; stage: "Additionally, compound 16e showed favorable pharmacokinetic characteristics and good antitumor efficacy in a SKOV3 xenograft model." [PMID:40939495]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zhengzhou Univ. METTL3 compound 16e.